Combinability of CRLX101 and Avastin? Established in Clinical Trial in Renal Cell Carcinoma

Patients treated with CRLX101 and Avastin at their respective MTDs did not require treatment discontinuations or dose reductions.

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Combinability-of-CRLX101-and-Avastin-Established-i/ArticleNewsFeed/Article/detail/824037?ref=25